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Injuries lead to a loss of more years of productivity than do
cancer and heart disease combined. More than 150000
people die each year in the USA as a result of trauma [1].
Hemorrhagic shock remains a major problem [2], occurring in
about 15% of trauma patients, and the mortality rate is 50%
in this group. Unfortunately, replacement blood is often not
available in the setting of traumatic hemorrhage because of
the paucity of universal donor-type blood, the length of time
required for type and cross-matching, and the limited blood
bank inventory secondary to the short shelf life of red blood
cells (RBCs) [3]. In addition, large volumes of transfusions
are given only reluctantly because of concerns about trans-
mission of viruses and the potentially immunosuppressive
nature of blood. Use of an alternative resuscitation fluid,
which functions both as a volume expander and an oxygen-
carrying fluid, may lead to improved outcomes in the critically
injured [4].
A variety of new agents are in phase III efficacy trials and offer
potential benefits when used for fluid replacement and as
oxygen therapeutic solutions [4]. These products have a long
shelf life, do not require type and cross-matching, are free of
viral or bacterial contamination, have a much lower viscosity
than blood, and may lack the immunosuppressive activity of
blood. Hemoglobin-based RBC substitutes have been shown
to have efficient oxygen transport properties. Safety remains a
concern, however, because early cell-free hemoglobin prepa-
rations demonstrated significant nephrotoxicity [5]. Some of
these solutions have been associated with pulmonary and
systemic hypertension [6], decreased cardiac output, and
decreased splanchnic perfusion, presumably mediated by a
nitric oxide scavenging effect [7]. Cross-linking and polymer-
izing hemoglobin subunits have reduced the incidence of
nephrotoxicity, but unwanted pressor effects have remained
problematic [4].
Recent studies have evaluated the utility of ultrapurified poly-
merized bovine hemoglobin (HBOC-201) as an oxygen-carry-
ing blood substitute [8]. Bovine hemoglobin administration
has been well tolerated in humans and improves oxygen deliv-
ery when compared with crystalloid infusion [9]. Phase III
trials with this product in elective orthopedic surgery were
recently completed. Prehospital and emergency center
trauma trials have been initiated in conjunction with the US
Department of Defense.
Promising research efforts by Northfield Laboratories (Evanston,
IL, USA) have centered on polymerized, pyridoxylated,
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Abstract
Persons who suffer traumatic injury are likely to be transfused with considerable amounts of blood
during initial resuscitation efforts. Oxygen-carrying solutions are currently in clinical testing as substitutes
for red blood cells. Although these agents may eliminate many concerns associated with blood
administration (short shelf life, infectious and immunologic risks, the need to type and cross-match), early
cell-free hemoglobin solutions demonstrated nephrotoxicity and were associated with pulmonary and
systemic hypertension, among other adverse events. Newer polymerized hemoglobin solutions show
acceptable safety profiles in the surgical setting and studies are being designed, some with funding
from the US Department of Defense, to evaluate their efficacy in hemorrhaging trauma victims.
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stroma-free human hemoglobin [4]. Polymerized hemoglobin
and banked RBCs have similar oxygen transport and oncotic
characteristics. In addition, this polymerized hemoglobin does
not appear to cause pulmonary or systemic hypertension
[10]. In a randomized prospective study of 44 trauma victims,
Gould and coworkers [3] found a reduced blood transfusion
requirement in patients receiving up to 6 units (300 g) of
polymerized hemoglobin during resuscitation (6.8 units
versus 10.4 units of packed RBCs in control individuals)
through day 1. No adverse effects related to polymerized
hemoglobin infusion were observed during the study. Phase III
trials in elective vascular and general surgery are ongoing. A
prehospital trauma trial has also been initiated in conjunction
with the US Department of Defense with this product.
The Canadian Department of National Defense is investigat-
ing an RBC substitute, namely HemoLink™ (Hemosol Inc.,
Mississauga, Ontario, Canada), which is an oligimeric hemo-
globin solution derived from outdated human blood. After
completing myriad preclinical and phase I safety trials,
Hemosol Inc. initiated four controlled randomized surgical
(orthopedic and cardiac) phase II studies focusing on both
safety and avoidance of transfusion [4]. The company has not
reported significant adverse effects. No published data from
the two clinical trials are currently available. A pivotal phase III
multicenter trial in coronary bypass patients was recently
completed in Canada and the UK.
Perfluorochemical emulsions (e.g. Fluosol-DA) initially
appeared promising because of their ability to carry large
amounts of dissolved oxygen. Unfortunately, clinical trials
showed a lack of effectiveness in the treatment of severe
anemia due to hemorrhage [11]. The second generation of
perfluorocarbons appears highly promising for use in iso-
volemic hemodilution [12], but phase III trials utilizing perflu-
bron – the latest perfluorocarbon – in the setting of cardiac
surgery were recently terminated.
In conclusion, three RBC substitute products are undergoing
multicenter efficacy trials (Table 1), using avoidance of trans-
fusion as the typical primary end-point [4]. Hopefully, these
studies will show the solutions to be safe and effective for
use both as volume expanders and as oxygen carriers. The
potential benefits to the hemorrhaging trauma patient are
immeasurable.
Competing interests
SMC is a consultant to Biopure, Hemosol Inc., and Baxter.
References
1. Arias E, Anderson RN, Kung H-C, Murphy SL, Kochanek KD:
Deaths: final data for 2001. Natl Vital Stat Rep 2003, 52:1-115.
2. Gould SA, Moore EE, Hoyt DB, Ness PM, Norris EJ, Carson JL,
Hides GA, Freeman IHG, DeWoskin R, Moss GS: The life-sus-
taining capacity of human polymerized hemoglobin when red
cells might be unavailable. J Am Coll Surg 2002, 195:445-452.
3. Gould SA, Moore EE, Hoyt DB, Burch JM, Haenel JB, Garcia J,
DeWoskin R, Moss GS: The first randomized trial of human
polymerized hemoglobin as a blood substitute in acute trauma
and emergent surgery. J Am Coll Surg 1998, 187:113-120.
4. Cohn SM: Blood substitutes in surgery. Surgery 2000,  127:
599-602.
5. Kjellstrom BT: Blood substitutes: where do we stand today? J
Intern Med 2003, 253:495-497.
6. Hess JR, MacDonald VW, Brinkley WW: Systemic and pul-
monary hypertension after resuscitation with cell-free hemo-
globin. J Appl Physiol 1993, 74:1769-1778.
7. Sharma AC, Singh G, Gulati A: Role of NO mechanism in car-
diovascular effects of diaspirin cross-linked hemoglobin in
anesthetized rats. Am J Physiol Heart Circ Physiol 1995, 269:
H1379-H1388.
8. Kasper SM, Grune F, Walter M, Amr N, Erasmi H, Buzello W: The
effects of increased doses of bovine hemoglobin on hemody-
namics and oxygen transport in patients undergoing preoper-
ative hemodilution for elective abdominal aortic surgery.
Anesth Analg 1998, 87:284-291.
9. Hughes GS Jr, Antal EJ, Locker PK, Francom SF, Adams WJ,
Jacobs EE Jr: Physiology and pharmacokinetics of a novel
hemoglobin-based oxygen carrier in humans. Crit Care Med
1996, 24:756-764.
10. Johnson JL, Moore EE, Offner PJ, Haenel JB, Hides GA, Tamura
DY:  Resuscitation of the injured patient with polymerized
stroma-free hemoglobin does not produce systemic or pul-
monary hypertension. Am J Surg 1998, 176:612-617.
Table 1
Red cell substitutes under active (phase III) investigation
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glutamer-bovine US Food and Drug Administration. Approved for use in
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Hemosol Inc. HemoLink™: Human O-raffinose polymerized Completed phase III multicenter trial in coronary
hemoglobin raffimer bypass patients in Canada and the UK. Planning
anemia trials in North America
DOD, Department of Defense.S17
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